Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial-Reference-Cited by-同舟云学术

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Published:2019-09-30 Issue:5 Volume:14 Page:527-539
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Shore Neal^ORCID,Zurth Christian,Fricke Robert,Gieschen Hille,Graudenz Kristina,Koskinen Mikko,Ploeger Bart,Moss Jonathan,Prien Olaf,Borghesi Gustavo,Petrenciuc Oana,Tammela Teuvo L.,Kuss Iris,Verholen Frank,Smith Matthew R.,Fizazi Karim

Funder

Bayer HealthCare

Orion Pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-019-00674-0.pdf

Reference33 articles.

1. National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer stat facts: prostate cancer. 2019. https://seer.cancer.gov/statfacts/html/prost.html. Accessed 16 May 2019.

2. Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, et al. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019;22(3):420–7. https://doi.org/10.1038/s41391-018-0121-2.

3. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013;14(12):1193–9. https://doi.org/10.1016/S1470-2045(13)70424-8.

4. Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, et al. The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev. 2017;55:71–82. https://doi.org/10.1016/j.ctrv.2017.03.001.

5. Stepney R, Lichtman SM, Danesi R. Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015. Ecancermedicalscience. 2016;10:611. https://doi.org/10.3332/ecancer.2016.611.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial;European Journal of Cancer;2024-11

2. Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors;JCO Oncology Practice;2024-09

3. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: prediction of in vivo drug-drug interactions;Chemico-Biological Interactions;2024-09

4. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments;Critical Reviews in Oncology/Hematology;2024-08

5. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes;JAMA Oncology;2024-06-01